Trial
NCT01055028
Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Stanford University
Collaborators
Genentech, Inc.
Condition
Angiosarcomas
Intervention
Bevacizumab
Why stopped
Poor accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-03-26